The Relationship Between Triglyceride to High-Density Lipoprotein Cholesterol Ratio and Cardiovascular High-Risk: A Cross-Sectional Investigation

Aims The triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio reflects the balance between atherogenic and anti-atherogenic lipid fractions. The study aims to investigate the utility of the TG/HDL-C ratio in identifying high-risk groups for cardiovascular disease (CVD) within the general population. Methods The current study was a branch of the ChinaHEART cohort in middle China that involved a total of 6,593 community-dwelling adults. We examine the association between TG/HDL-C and CVD high-risk in a cross-sectional investigation. Results Results from restricted cubic spline and ROC analyses revealed a significant relationship between higher TG/HDL-C levels and increased odds of cardiovascular high-risk, with the ratio exhibiting good discriminatory power (AUC=0.819 in the fully adjusted model). Logistic regression further supported this association, indicating a 1.21-fold rise in the odds of high-risk for each unit increase in TG/HDL-C. Conclusions The TG/HDL ratio demonstrates potential as a valuable clinical tool for CVD prevention. By incorporating the TG/HDL ratio into risk assessment models, healthcare professionals can enhance risk stratification and identify high-risk individuals who may benefit from targeted interventions. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial NCT02536456 ### Funding Statement Yes ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Not Applicable The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study was conducted with approval from the Ethics Committee of Fuwai Hospital and the Ethics Committee of Luohe Central Hospital. This study was conducted in accordance with the declaration of Helsinki. Written informed consent was obtained from all participants. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Not Applicable I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Not Applicable I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Not Applicable The data underlying the results presented in the study are available from Haoran Wang(washingtonhr{at}163.com).